The FMS like Tyrosine Kinase 3 (FLT3) Is Overexpressed in a Subgroup of Multiple Myeloma Patients with Inferior Prognosis
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The FMS like Tyrosine Kinase 3 (FLT3) Is Overexpressed in a Subgroup of Multiple Myeloma Patients with Inferior Prognosis
Authors
Keywords
-
Journal
Cancers
Volume 12, Issue 9, Pages 2341
Publisher
MDPI AG
Online
2020-08-19
DOI
10.3390/cancers12092341
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- CIC Mutation as a Molecular Mechanism of Acquired Resistance to Combined BRAF‐MEK Inhibition in Extramedullary Multiple Myeloma with Central Nervous System Involvement
- (2019) Matteo Claudio Da Vià et al. ONCOLOGIST
- Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study
- (2018) Sigrun Thorsteinsdottir et al. HAEMATOLOGICA
- Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study
- (2018) Sigrun Thorsteinsdottir et al. HAEMATOLOGICA
- Drug resistance in multiple myeloma
- (2018) Pawel Robak et al. CANCER TREATMENT REVIEWS
- Towards personalized treatment in multiple myeloma based on molecular characteristics
- (2018) Charlotte Pawlyn et al. BLOOD
- FLT3 inhibitors in acute myeloid leukemia
- (2018) Mei Wu et al. Journal of Hematology & Oncology
- FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions
- (2017) Maria Larrosa-Garcia et al. MOLECULAR CANCER THERAPEUTICS
- High levels of FLT3-ligand in bone marrow and peripheral blood of patients with advanced multiple myeloma
- (2017) Normann Steiner et al. PLoS One
- Integration of Novel Agents into the Care of Patients with Multiple Myeloma
- (2016) Robert Z. Orlowski et al. CLINICAL CANCER RESEARCH
- New Developments in Diagnosis, Prognosis, and Assessment of Response in Multiple Myeloma
- (2016) Ola Landgren et al. CLINICAL CANCER RESEARCH
- Clonal Evolution in Multiple Myeloma
- (2016) Bita Fakhri et al. Clinical Lymphoma Myeloma & Leukemia
- Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
- (2015) Antonio Palumbo et al. JOURNAL OF CLINICAL ONCOLOGY
- Potential role of FLT3-ligand in the angiogenic process of multiple myeloma
- (2015) M. Kokonozaki et al. LEUKEMIA RESEARCH
- International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
- (2014) S Vincent Rajkumar et al. LANCET ONCOLOGY
- Improved long-term survival in multiple myeloma up to the age of 80 years
- (2014) S Y Kristinsson et al. LEUKEMIA
- Biologic Frontiers in Multiple Myeloma: From Biomarker Identification to Clinical Practice
- (2013) O. Landgren et al. CLINICAL CANCER RESEARCH
- Antimyeloma activity of the sesquiterpene lactone cnicin: impact on Pim-2 kinase as a novel therapeutic target
- (2011) Karin Jöhrer et al. JOURNAL OF MOLECULAR MEDICINE-JMM
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started